A phase 3 study to determine the efficacy and safety of recombinant human activated protein C in severe sepsis

Conditions

Severe sepsis Infections and Infestations Sepsis

Laura M. Palma Medina, Eivind Rath, Sanjeevan Jahagirdar, Trond Bruun, Martin Bruun Madsen et al. (17 authors)

Journal of Clinical Investigation2021-07-1419 citations

Prediction of disease severity in young children presenting with acute febrile illness in resource-limited settings: a protocol for a prospective observational study

Arjun Chandna, Endashaw M. Aderie, Riris Andono Ahmad, Eggi Arguni, Elizabeth A. Ashley et al. (33 authors)

BMJ Open2021-01-0118 citations

10.1136/bmjopen-2020-045826

Interventions

Recombinant human activated protein C (tradename - Xigris, generic name - drotrecogin alfa [activated]) versus placebo. This trial took place at 164 hospitals in 11 countries.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Not provided at time of registration

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

Belgium, Canada, France, Spain, United States of America

Outcome results

None listed